Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Moderna Stock Dove by Nearly 10% on Monday

By Eric Volkman - Dec 28, 2020 at 5:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were apparently spooked by news of one patient's allergic reaction following inoculation.

What happened

Though the FDA recently gave emergency use authorization (EUA) to Moderna's ( MRNA -4.86% ) mRNA-1273 coronavirus vaccine, the company's stock was a big dud on Monday. This was likely due to some scary-sounding news regarding one patient who was administered the vaccine before Christmas.

So what

The New York Times reported on Friday that Dr. Hossein Sadrzadeh, a geriatric oncology fellow at Boston Medical Center, said he developed a severe allergic reaction just after receiving his initial jab of mRNA-1273's two-dose regimen.

Minutes after getting his shot, Sadrzadeh said he experienced dizziness and an increased heart rate. He was allowed to administer epinephrine to himself with an EpiPen, which he keeps on hand due to a severe shellfish allergy.

Gloved hand filling a syringe from a vial.

Image source: Getty Images.

Boston Medical Center said that after his self-treatment the doctor was "evaluated, treated, observed, and discharged." It added that on Friday, he was doing well.

Moderna's vaccine is only the second of two coronavirus vaccines to receive an EUA; the first was Pfizer ( PFE 2.72% ) and BioNTech's ( BNTX -2.22% ) BNT162b2. Moderna was granted its authorization on Dec. 18, six days after Pfizer and BioNTech received theirs.

Now what

No biotech investor wants to hear about a reaction like Sadrzadeh's to their vaccine or drug, especially mere days after its authorization by a regulator. We still don't know precisely how effective mRNA-1273 will prove to be in mass inoculations, but we should remember that occasional adverse reactions are not unusual for any vaccine or treatment. Moderna didn't deserve such a sell-off on this news.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$350.62 (-4.86%) $-17.89
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.83 (2.72%) $1.43
BioNTech SE Stock Quote
BioNTech SE
BNTX
$354.48 (-2.22%) $-8.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.